Hospital
Logan Health - Whitefish
Logan Health - Whitefish was paid $706K by Medicaid between Jan 2018 and Dec 2024, across 213 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoLOGAN HEALTH - WHITEFISH
WHITEFISH, MT 59937
WHITEFISH, MT 59937
33aNPI1396710851assigned 02/20/2006
33bProvider typeCritical Access Hospital
28Total paid$706K
24GClaims304,789
24DCodes billed213
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Montana
Rank by total paid#7 of 25
Median peer was paid$185K
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ABEL, KEVIN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,634 | $112K | |
| 2019 | 44,075 | $128K | |
| 2020 | 38,078 | $121K | |
| 2021 | 47,897 | $102K | |
| 2022 | 53,382 | $82K | |
| 2023 | 49,373 | $104K | |
| 2024incomplete | 30,350 | $57K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 9,071 | 8,224 | $146K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 5,541 | 4,959 | $77K |
| D2930 | Prefabricated stainless steel crown - primary tooth | 8.2% | 2,197 | 534 | $58K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.0% | 2,433 | 1,983 | $57K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.6% | 5,605 | 4,475 | $54K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.3% | 1,871 | 1,756 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 5,679 | 4,444 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 1,627 | 1,381 | $17K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 9,481 | 2,766 | $13K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 4,018 | 2,713 | $13K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.8% | 3,335 | 3,054 | $13K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 1,421 | 1,309 | $11K |
201 more codes
| 71045 | Radiologic examination, chest; single view | 1.5% | 3,750 | $10K |
| 87631 | 1.4% | 4,591 | $10K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 18,678 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 6,092 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 2,671 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 5,426 | $8K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 562 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,610 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,152 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,020 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,608 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 435 | $4K |
| 96376 | <1% | 1,806 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,432 | $4K |
| 87070 | <1% | 1,820 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,160 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 194 | $3K |
| 59025 | Fetal non-stress test | <1% | 1,232 | $3K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 142 | $3K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 241 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,112 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,395 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,882 | $2K |
| 80050 | General health panel | <1% | 1,695 | $2K |
| 83690 | <1% | 3,859 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 473 | $2K |
| 84703 | <1% | 1,824 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,646 | $2K |
| J3490 | Unclassified drugs | <1% | 3,395 | $2K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 193 | $2K |
| 81001 | <1% | 5,376 | $2K | |
| 73562 | <1% | 114 | $2K | |
| 81003 | <1% | 6,035 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 636 | $2K |
| 73110 | <1% | 99 | $2K | |
| 86141 | <1% | 1,644 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 432 | $2K |
| 87186 | <1% | 2,350 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 443 | $2K |
| 87077 | <1% | 2,780 | $2K | |
| 73610 | <1% | 214 | $2K | |
| 81025 | <1% | 2,720 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,090 | $1K |
| 83605 | <1% | 2,180 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,298 | $1K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 815 | $1K |
| 87088 | <1% | 2,487 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 78 | $1K |
| 80306 | <1% | 1,644 | $1K | |
| 84439 | <1% | 2,787 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,397 | $1K |
| 73630 | <1% | 153 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 470 | $1K |
| 87040 | <1% | 1,097 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,777 | $1K |
| 84481 | <1% | 1,489 | $1K | |
| 84484 | <1% | 4,072 | $932.65 | |
| 36000 | <1% | 460 | $924.89 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 494 | $887.28 |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $882.57 |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,079 | $837.93 |
| 83735 | <1% | 4,122 | $835.26 | |
| 80061 | Lipid panel | <1% | 4,580 | $790.94 |
| 73030 | <1% | 197 | $778.95 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 81 | $758.92 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,753 | $750.07 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 39 | $712.66 |
| 80179 | <1% | 197 | $654.14 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 380 | $587.30 |
| 82607 | <1% | 1,568 | $577.82 | |
| 87486 | <1% | 209 | $573.24 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,323 | $571.89 |
| 86140 | <1% | 915 | $555.36 | |
| 85027 | <1% | 3,037 | $553.60 | |
| 82728 | <1% | 797 | $546.69 | |
| 82077 | <1% | 1,339 | $544.05 | |
| 87581 | <1% | 209 | $541.50 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 276 | $534.99 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 403 | $531.98 |
| 76770 | <1% | 12 | $526.35 | |
| 85652 | <1% | 2,089 | $478.92 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 738 | $429.96 |
| 84466 | <1% | 519 | $382.62 | |
| 80305 | <1% | 490 | $372.44 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 140 | $368.60 |
| 83540 | <1% | 1,184 | $368.30 | |
| 97162 | <1% | 235 | $350.22 | |
| 80143 | <1% | 219 | $339.37 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 818 | $317.70 |
| 12001 | <1% | 12 | $287.59 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 54 | $283.49 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 567 | $282.69 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 575 | $247.46 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,086 | $234.77 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,177 | $204.26 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 13 | $203.17 |
| 85610 | <1% | 3,632 | $201.71 | |
| 86850 | <1% | 1,636 | $199.11 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 134 | $196.87 |
| 74018 | <1% | 18 | $194.57 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 76 | $168.58 |
| 84403 | <1% | 390 | $167.24 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 36 | $159.98 |
| 83550 | <1% | 590 | $155.43 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 722 | $147.14 |
| 73564 | <1% | 12 | $127.36 | |
| 97161 | <1% | 120 | $126.98 | |
| 86901 | <1% | 1,468 | $112.54 | |
| 84550 | <1% | 421 | $109.94 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 397 | $106.69 |
| 85379 | <1% | 507 | $106.48 | |
| 76642 | <1% | 65 | $105.67 | |
| 86803 | <1% | 568 | $104.56 | |
| 85730 | <1% | 1,213 | $102.50 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 60 | $98.28 |
| 82746 | <1% | 374 | $95.28 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 154 | $92.70 |
| 96367 | <1% | 55 | $91.29 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 100 | $78.96 |
| A9150 | Non-prescription drugs | <1% | 532 | $76.33 |
| 86900 | <1% | 1,292 | $66.87 | |
| 87205 | <1% | 87 | $66.80 | |
| 86200 | <1% | 14 | $62.94 | |
| 83001 | <1% | 141 | $60.20 | |
| 87340 | <1% | 457 | $57.38 | |
| 82570 | <1% | 781 | $53.24 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 309 | $52.39 |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 175 | $50.80 |
| 82670 | <1% | 268 | $45.26 | |
| 86780 | <1% | 253 | $42.88 | |
| 86038 | <1% | 28 | $39.16 | |
| 97035 | <1% | 445 | $30.84 | |
| 83880 | <1% | 564 | $30.15 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 220 | $26.57 |
| 82330 | <1% | 38 | $22.16 | |
| 87081 | <1% | 237 | $21.48 | |
| A9270 | Non-covered item or service | <1% | 431 | $19.50 |
| 81002 | <1% | 264 | $16.92 | |
| 86430 | <1% | 28 | $12.18 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 50 | $11.47 |
| 87015 | <1% | 135 | $10.82 | |
| 82550 | <1% | 193 | $10.55 | |
| 82950 | <1% | 114 | $7.69 | |
| 85014 | <1% | 311 | $7.68 | |
| 85018 | <1% | 242 | $7.68 | |
| 85007 | <1% | 215 | $7.38 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 651 | $0.00 |
| 90837 | Psychotherapy session, about an hour | 0% | 274 | $0.00 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 72 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 632 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 16 | $0.00 |
| 82948 | 0% | 295 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 53 | $0.00 |
| 84156 | 0% | 179 | $0.00 | |
| 87210 | 0% | 13 | $0.00 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 249 | $0.00 |
| 82947 | 0% | 47 | $0.00 | |
| 82565 | 0% | 39 | $0.00 | |
| 90715 | 0% | 31 | $0.00 | |
| 82805 | 0% | 49 | $0.00 | |
| 84702 | 0% | 178 | $0.00 | |
| 80076 | 0% | 13 | $0.00 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 0% | 29 | $0.00 |
| 97116 | 0% | 19 | $0.00 | |
| 83970 | 0% | 12 | $0.00 | |
| 72100 | 0% | 13 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| 84100 | 0% | 26 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 28 | $0.00 |
| 73130 | 0% | 28 | $0.00 | |
| D2929 | 0% | 51 | $0.00 | |
| 80375 | 0% | 14 | $0.00 | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 0% | 17 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 650 | $0.00 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 0% | 147 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 736 | $0.00 |
| 82553 | 0% | 149 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 45 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 83 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 30 | $0.00 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 157 | $0.00 |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 0% | 24 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 110 | $0.00 |
| 82043 | 0% | 27 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 15 | $0.00 |
| 76830 | Ultrasound, transvaginal | 0% | 134 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 26 | $0.00 |
| 93971 | 0% | 19 | $0.00 | |
| 97165 | 0% | 35 | $0.00 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | 0% | 18 | $0.00 |
| 90834 | Psychotherapy session, about 45 minutes | 0% | 89 | $0.00 |
| 84144 | 0% | 19 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 27 | $0.00 |
| 80329 | 0% | 14 | $0.00 | |
| 80320 | 0% | 13 | $0.00 | |
| 81015 | 0% | 13 | $0.00 | |
| 76801 | 0% | 15 | $0.00 | |
| 86376 | 0% | 37 | $0.00 | |
| 86762 | 0% | 44 | $0.00 | |
| 96368 | 0% | 17 | $0.00 | |
| 80051 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialABEL, KEVIN (PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.